Overview
The objective of this post-market registry is to assess the safety and performance of the Lifetech Cera™ VSD occluder in a real-world and on-label fashion.
Description
The study intends to collect data from patients who have implanted with the device before 2022. The study is expected to completed by the end of 2024.
Eligibility
Inclusion Criteria:
- Patients with a confirmed diagnosis of Ventricular Septal Defect (VSD) and implanted with the investigational device as per IFU instructions
Exclusion Criteria:
- Patients did not conduct any follow up visit after hospital discharge.
